Key facts
- What it is: Octreotide is a synthetic somatostatin analog available in short-acting and long-acting formulations.
- Evidence: Strong human evidence across endocrine and neuroendocrine indications.
- Status: FDA-approved somatostatin analog.
- Main caution: Gallstones, gastrointestinal effects, glucose disruption, slowed heart rate, and thyroid changes are important monitoring considerations.
- Sources: 5 PubMed-indexed papers linked below.
What is Octreotide?
Octreotide is a synthetic somatostatin analog available in short-acting and long-acting formulations. It suppresses secretion of several hormones and is used in acromegaly and severe symptoms from certain neuroendocrine tumors, with additional specialist uses depending on context.
The first SEO trap with peptide content is treating every compound as if it belongs to the same category. It does not. Some peptides are approved prescription medicines supported by randomized trials; others are endogenous signaling molecules being studied in cells; others are unapproved chemicals sold with no regulated manufacturing chain. For Octreotide, the evidence and regulatory category above determine what conclusions are reasonable.
This guide does not provide a dose, cycle, protocol, source, or personal recommendation. It translates published research so readers can distinguish a measured result from a marketing claim and bring better questions to a licensed clinician.
How does Octreotide work?
Octreotide binds somatostatin receptors, especially SSTR2, reducing growth hormone and multiple gastrointestinal hormones. In neuroendocrine tumors, receptor expression enables symptom control, antiproliferative treatment, imaging, and receptor-targeted radionuclide therapy.
Mechanism is not the same as clinical benefit. A compound can activate a receptor, change a biomarker, or improve an animal model without improving how people feel, function, or survive. The strongest medical claims require controlled human outcomes, not a plausible pathway alone.
What does the research on Octreotide show?
Decades of clinical use support biochemical control in acromegaly and symptom control in secretory tumors. PROMID showed delayed tumor progression with long-acting octreotide in metastatic midgut neuroendocrine tumors, and NETTER-1 used octreotide as the control backbone for radioligand therapy.
These papers were selected to show the shape of the evidence: foundational biology, clinical trials where they exist, safety signals, and reviews that place single studies in context. A citation does not mean PepMate endorses a treatment; it lets readers inspect the original record.
How strong is the evidence?
Evidence assessment: Strong human evidence across endocrine and neuroendocrine indications. Response depends on tumor type, receptor expression, disease burden, and endpoint. Symptom suppression does not always equal tumor shrinkage.
Evidence strength depends on study design, directness, replication, sample size, and whether researchers measured a meaningful outcome. Animal evidence can justify a human trial, but it cannot establish a human treatment. Observational human data can identify associations, but it cannot reliably prove cause and effect.
Is Octreotide approved or available?
FDA-approved somatostatin analog. Approval is tied to a specific product, indication, population, formulation, and regulator. “Research use only,” clinic availability, compounding, or a listing on a peptide website is not the same as approval. Availability can change, so current regulator labeling and professional guidance take priority over any static article.
Octreotide safety, risks, and evidence gaps
Gallstones, gastrointestinal effects, glucose disruption, slowed heart rate, and thyroid changes are important monitoring considerations. Long-acting therapy requires specialist follow-up.
Response depends on tumor type, receptor expression, disease burden, and endpoint. Symptom suppression does not always equal tumor shrinkage.
Unapproved online peptides add risks that a paper about a verified laboratory compound cannot measure: mislabeling, contamination, sterility failure, degradation, and a concentration different from the label. Even an endogenous or short peptide can cause harm when the route, exposure, or manufacturing quality changes.
Frequently asked questions
What is Octreotide?
Octreotide is a synthetic somatostatin analog available in short-acting and long-acting formulations. It suppresses secretion of several hormones and is used in acromegaly and severe symptoms from certain neuroendocrine tumors, with additional specialist uses depending on context.
How does Octreotide work?
Octreotide binds somatostatin receptors, especially SSTR2, reducing growth hormone and multiple gastrointestinal hormones. In neuroendocrine tumors, receptor expression enables symptom control, antiproliferative treatment, imaging, and receptor-targeted radionuclide therapy.
Is Octreotide FDA-approved?
FDA-approved somatostatin analog. Approval is indication-specific and can differ by country; check current regulator labeling rather than relying on peptide-shop descriptions.
What does PubMed research on Octreotide show?
Decades of clinical use support biochemical control in acromegaly and symptom control in secretory tumors. PROMID showed delayed tumor progression with long-acting octreotide in metastatic midgut neuroendocrine tumors, and NETTER-1 used octreotide as the control backbone for radioligand therapy.
What are the main risks of Octreotide?
Gallstones, gastrointestinal effects, glucose disruption, slowed heart rate, and thyroid changes are important monitoring considerations. Long-acting therapy requires specialist follow-up.
PubMed sources
Every medical claim in this guide is anchored to peer-reviewed or scholarly literature indexed on PubMed. Open the abstracts below to review the study design, population, and limitations.
- Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. — PubMed 19704057 (2009)
- Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors. — PubMed 28076709 (2017)
- Octreotide. — PubMed 8532003 (1996)
- Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. — PubMed 8404961 (1993)
- Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. — PubMed 10774879 (2000)
Source selection and update method: PepMate Research Editorial Policy. Last updated 22 July 2026.